Colesevelam - Cosmo Pharmaceuticals
Alternative Names: CB-01-33; Colesevelam hydrochloride-MMXLatest Information Update: 13 Jan 2026
At a glance
- Originator Cosmo Pharmaceuticals
- Developer Cosmo Technologies
- Class Amines; Antihyperglycaemics; Antihyperlipidaemics; Digestion aids; Polymers
- Mechanism of Action Bile acid binding protein modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Primary bile acid malabsorption
Most Recent Events
- 22 Dec 2025 Phase-II clinical trials in Primary bile acid malabsorption in Romania (PO) (CTIS2024-511993-55-00)
- 09 Dec 2025 Phase-II clinical trials in Primary bile acid malabsorption in Denmark (PO) (CTIS2024-511993-55-00)
- 26 Nov 2025 Phase-II clinical trials in Primary bile acid malabsorption in Italy (PO) (CTIS2024-511993-55-00)